Celecoxib 化学構造
分子量: 381.37

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare COX Inhibitors
    COX製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット COX-2
IC50 40 nM [1]
In vitro試験 Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549 NVPSUldUTnWwY4Tpc44hSXO|YYm= Mnr0NE4yNTNyIN88US=> M3uzXFQ5KGh? MVnpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MVuyOlUyOzF5Mh?=
H460 NHjOTHdHfW6ldHnvckBCe3OjeR?= MUOwMlEuOzBizszN M4LjclQ5KGh? MnP1bY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> NXTpV|I3OjZ3MUOxO|I>
HKESC-2 NEC0OWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPJeXNLOjEEoN88US=> NFzHemk1QMLiaNMg M1rL[ZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? M1[xbVI3PDd2Nkmz
CaES-17 M{iwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LkTlIxyqEQvF2= NELEZnc1QMLiaNMg MYTzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> Mk\3NlY1PzR4OUO=
HKESC-2 M37LfmFxd3C2b4Ppd{BCe3OjeR?= M{LsUFIxyqEQvF2= MYO0POKhcMLi M{P0fJJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NUfYU29NOjZ2N{S2PVM>
CaES-17 MkOxRZBweHSxc3nzJGF{e2G7 NUDSd|BXOjEEoN88US=> M1rMelQ5yqCqwrC= NET0RoVz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MVKyOlQ4PDZ7Mx?=
A549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;6U4g5PS1zNkCg{txO MYW0POKhcMLi MULEUXNQ NYWwfFNlUUN3ME2xOlMvPCEQvF2= MVKyOlQ3PDZ2Mx?=
HCC827 M1XTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HGZlUuOTZyIN88US=> MlXqOFjDqGkEoB?= MXXEUXNQ MVvJR|UxRTZ7LkKg{txO M1fOTlI3PDZ2NkSz
A549 NGfuT49CeG:ydH;zbZMhSXO|YYm= M17RN|gxKML3TR?= M4WwR|Q5yqCqwrC= MmjjSG1UVw>? M3e5Zolv\HWlZYOgZZBweHSxc3nz NWLp[2d4OjZ2NkS2OFM>
HCC827 M1XtRWFxd3C2b4Ppd{BCe3OjeR?= MX:4NEDDvU1? NYX5WoVoPDkEoHlCpC=> M1XnbGROW09? M4S1colv\HWlZYOgZZBweHSxc3nz NHuxUFgzPjR4NE[0Ny=>
SGC-7901/DDP NH;6R2VHfW6ldHnvckBCe3OjeR?= NIG4bXAyOMLiwsXN M1nJVFI1KGh? NE\pdIJqdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v M3\RR|I3PDB5NkWz
SGC-7901  NWnOUpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rpO|I1yqCqwrC= MYPJR|UxRTFzNT6wPEDPxE1? NHXhPJMzPjRyN{[1Ny=>
SGC-7901/DDP NHOwVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUeyOOKhcMLi NYTyS3FvUUN3ME2zOU41PSEQvF2= MmXvNlY1ODd4NUO=
SGC-7901/DDP NILnVFdCeG:ydH;zbZMhSXO|YYm= NF\LOnoyOMLiwsXN NFrpZ2czPCCq MUjpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKHerdHigZ4l{eGyjdHnu NFmwVWszPjRyN{[1Ny=>
SGC-7901/DDP MYPGeY5kfGmxbjDBd5NigQ>? NYXpWJRUOTEEoNM1US=> NF3aOlgzPCCq M3fucolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLi NX3XdVFEOjZ2MEe2OVM>
SGC-7901/DDP MX7GeY5kfGmxbjDBd5NigQ>? NHf4[FcyOMLiwsXN MkTKNlQhcA>? NWTo[oRj[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv MV:yOlQxPzZ3Mx?=
H357 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1O{42NzFyIN88US=> MmL4OFghcA>? NV[2R|JMTE2VTx?= MVHpcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4 NYPwVY17OjZyMEm4O|Q>
TAF MX7GeY5kfGmxbjDBd5NigQ>? MUSxNOKhyrWP NIf1XVA4KGR? Mo\EZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN? NHLiOIIzPTl6N{GyOy=>
TAF M2nDUWZ2dmO2aX;uJGF{e2G7 NYq4VppuOTEEoNM1US=> NX7EVIQxOzBvMUKwJI1qdg>? MlHQdI9wemy7IHHm[oVkfHNiZFHreEBxcG:|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n MojFNlU6QDdzMke=
TAF MnqySpVv[3Srb36gRZN{[Xl? M1XjelExyqEEtV2= M361NlQ5KGh? MofObY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M{Pub|I2QTh5MUK3
PANC-1 NHnoXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrsNlAwPjBxMUCwJO69VQ>? NYr0TFBvOjRxNEivO|IhcA>? M1HxcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NF3TVVAzPTl5M{C2Ni=>
PANC-1 NVTqdVNZTnWwY4Tpc44hSXO|YYm= NHLueW8zOC94MD:xNFAh|ryP MkmyNlQhcA>? M{O3TIF1fGWwdXH0d{Bk\WyuIHnueoF{cW:wIHHu[EBucWe{YYTpc44hcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NGnyfYwzPTl5M{C2Ni=>
HeLa  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWyfJUzOMLizszNxsA> MYWyOOKhcA>? M{G5UYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w NVXmbFB[OjV5N{C0NlM>
SACC-83 NFyySHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO5NZFtOjEEoN88UeKh MXyyOOKhcA>? NW\jdmhy\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= MV[yOVc4ODR{Mx?=
HeLa  M3vuVGFxd3C2b4Ppd{BCe3OjeR?= M3LzUFIxyqEQvF5CpC=> M4nmS|I1yqCq M37DZ4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> MoTINlU4PzB2MkO=
SACC-83 NIHl[FVCeG:ydH;zbZMhSXO|YYm= NHnjepEzOMLizszNxsA> MlrmNlTDqGh? NGPYeoJmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ NV3mXnk3OjV5N{C0NlM>
HeLa  NHjVUHlHfW6ldHnvckBCe3OjeR?= Mne3NlAwPDBxOECg{txO MXGyOOKhcA>? MUj1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NVvCbmVXOjV5N{C0NlM>
SACC-83 MVvGeY5kfGmxbjDBd5NigQ>? M4TRVVIxNzRyL{iwJO69VQ>? MXKyOOKhcA>? MWf1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NGPS[Y8zPTd5MESyNy=>
HLCZ01 NYHTZVNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuxU3kzOOLCk{[wxsDDvU1? M3yzOFQ5KGh? M3SxXWROW09? MkHLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MW[yOVczPDh7OR?=
HLCZ01 MmT2SpVv[3Srb36gRZN{[Xl? MY[0NOKh|ryP MlvQNlQhcA>? M3nUSWROW09? Ml:0bY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=> MmXSNlU4OjR6OUm=
HLCZ01 MYjBdI9xfG:|aYOgRZN{[Xl? MnnTOFDDqM7:TR?= NXXtcIJ2OjRiaB?= MWrEUXNQ MmPj[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y M{XISFI2PzJ2OEm5
HLCZ01 MnTLSpVv[3Srb36gRZN{[Xl? MYO0NOKh|ryP NFH4bXIzPCCq NGjlZWZFVVOR NEL3OXhqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE> MoSzNlU4OjR6OUm=
MGC803 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvOfHYxNTZyIN88US=> NFj0XYk4OiCq NY\oeoJQUUN3ME20O{4zPeLCidMx5qCKPi52MzFOwG0> M2nTOVI2PzBzM{e4
SGC7901 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HmW|AuPjBizszN NYHZZndQPzJiaB?= NU\afGx1UUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> MoL6NlU4ODF|N{i=
MGC803 MVvGeY5kfGmxbjDBd5NigQ>? M170[VQxyqEQvF2= MVq4M|E3NzJ2IHi= MkXEeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u MorLNlU4ODF|N{i=
SGC7901 MXHGeY5kfGmxbjDBd5NigQ>? M3vvc|QxyqEQvF2= MkTVPE8yPi9{NDDo MWP1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= NFHGWYYzPTdyMUO3PC=>
MCF-7  M2PNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDG[G5KOS9zMDFOwG0> MlH3O|IhcA>? MUnEUXNQ MmfO[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? MnHYNlU3Pjd3MUC=
MDA-MB-231  MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[2NU8yOCEQvF2= NXTITYhiPzJiaB?= M4mwN2ROW09? M3\WToVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w NXjZWo1GOjV4Nke1NVA>
MDA-MB-231 NXz3S4xNTnWwY4Tpc44hSXO|YYm= MmnsNE01OCEEtV2= NG\m[5A1NTJ2IHi= Mm\5bY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHfq[nkzPTV6N{OyPS=>
MCF-7 M2XvfGZ2dmO2aX;uJGF{e2G7 M1;ybFAuPDBiwsXN M4LiNFQuOjRiaB?= MnfR[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? MnThNlU2QDd|Mkm=
MCF7-MX  Mle5SpVv[3Srb36gRZN{[Xl? MlXHNE01OCEEtV2= M3LWT|QuOjRiaB?= M1PMd4VvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NVjOfmtwOjV3OEezNlk>
MDA-MB-231 M4HN[WZ2dmO2aX;uJGF{e2G7 NX7XbpF[OC12MDFCuW0> NEj2U3Y1NTJ2IHi= M1T6UJN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?= MV[yOVU5PzN{OR?=
A2780 MlXZSpVv[3Srb36gRZN{[Xl? MmnHOU8yOC9zNTFOwG0> NGLkNW81QCCq NVH6PHR6\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MknBNlU1OjR6OUi=
SKOV3  MVPGeY5kfGmxbjDBd5NigQ>? MkDIOU8yOC9zNTFOwG0> MUm0PEBp M2jQSIRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlXVNlU1OjR6OUi=
A2780 M4i0UmZ2dmO2aX;uJGF{e2G7 NGXhflc2NzFyL{G1JO69VQ>? MV60PEBp M2LOOIVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? M1LuNVI2PDJ2OEm4
SKOV3  NHe3Z|ZHfW6ldHnvckBCe3OjeR?= MnW5OU8yOC9zNTFOwG0> MXO0PEBp NXjjTYVD\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= MUSyOVQzPDh7OB?=
A2780 MVXGeY5kfGmxbjDBd5NigQ>? MYW1M|ExNzF3IN88US=> NY\JfYdoPDhiaB?= MW\k[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? M17rRlI2PDJ2OEm4
SKOV3  NHnoZ29HfW6ldHnvckBCe3OjeR?= M2TzUFUwOTBxMUWg{txO NWWwTmZqPDhiaB?= M3nRT4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= M374XlI2PDJ2OEm4
A2780 NHG4VG1HfW6ldHnvckBCe3OjeR?= M2n6SVUwOTBxMUWg{txO NGr2UZEyKGh? NEfBPGVqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkPUNlU1OjR6OUi=
SKOV3  NXm5RpBJTnWwY4Tpc44hSXO|YYm= Ml3ROU8yOC9zNTFOwG0> NVvhPGE2OSCq NHzISY9qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX\iepA{OjV2MkS4PVg>
HCT-15 MYLGeY5kfGmxbjDBd5NigQ>? MofpNVAuPTBizszN MXq2MVM3KGh? NVruXpMzcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NVexeYxpOjV{MUiwNlg>
HT-29  M13hVmZ2dmO2aX;uJGF{e2G7 MYmxNE02OCEQvF2= M1i3VlYuOzZiaB?= NUj1OmF5cW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NH3xXoYzPTJzOECyPC=>
HSC3  NX:2[mJtS2WubDDWbYFjcWyrdImgRZN{[Xl? M3n1SFDjiJN2MDFOwG0> NVPQN3ZSPDhiaB?= M3j2[mlEPTB;MkWuOeKyOS55OECg{txO MWiyOVE6QDd6OR?=
HSC3  NFXFcpFCeG:ydH;zbZMhSXO|YYm= MW[yOUDPxE1? M{HEb|Q5KGh? NXzOVZM1cW6mdXPld{BieG:ydH;zbZM> NGrn[XUzPTF7OEe4PS=>
HSC3  NHXR[4hHfW6ldHnvckBCe3OjeR?= NHf0fm0zPSEQvF2= M4r4e|Q5KGh? M2PacoV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? NXP4bY1tOjVzOUi3PFk>
HSC3  NFP2TnBHfW6ldHnvckBCe3OjeR?= NHfCbmwzPSEQvF2= NFvoSGs1QCCq M37lWYlvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> NU\hTWZxOjVzOUi3PFk>
HSC3  NUPqU|FxTnWwY4Tpc44hSXO|YYm= NHLNc2UzPSEQvF2= MmnTO|IhcA>? MVjk[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= M3\FeFI2OTl6N{i5
201T  M3zOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq3NkBp NWHMb2N2TE2VTx?= NYTiS3ZrUUN3ME20PE43KML3TR?= NITJcIIzPTB3N{m0NS=>
273T NYTTW4NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV63ZWlvPzJiaB?= NGjsZoJFVVOR M4jaOWlEPTB;OECuOUDDvU1? M3vlZ|I2ODV5OUSx
Hep-2 NEj5SG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUezNE82OC9zMECg{txO MlX3NVIwOjRxM{[vOFghcA>? MmTUSG1UVw>? NEjGb5VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1XwNVI1QTl6NU[0
Hep-2 MlXORZBweHSxc3nzJGF{e2G7 NFHFOo42OCEQvF2= MmC5NE01QCCq NGXiU4JFVVOR MXPpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= M2n1e|I1QTl6NU[0
Hep-2 NYrzWld4TnWwY4Tpc44hSXO|YYm= NHPXVGQ2OCEQvF2= MYiwMVQ5KGh? MmO5SG1UVw>? NWi0PFZ7emWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= NIizN|EzPDl7OEW2OC=>
Hep-2 MmrySpVv[3Srb36gRZN{[Xl? MV61NEDPxE1? Mn\yNE01QCCq MUfEUXNQ NWW5fFA{\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? NHTsTG4zPDl7OEW2OC=>
SGC-7901 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[xNE82OC9zMECg{txO Mn\yNlQwPDhxN{KgbC=> NIq2e4JFVVOR M2joZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NHrTN4IzPDl7Mkm1PC=>
MKN-45 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G5WlExNzVyL{GwNEDPxE1? MVuyOE81QC95MjDo M1TlbmROW09? M3TYUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NEHKUokzPDl7Mkm1PC=>
SGC-7901 NULLelNpTnWwY4Tpc44hSXO|YYm= NYLNW2pXOTBxNUCvNVAxKM7:TR?= NUThXI1NPDhiaB?= M3HXU2ROW09? Mlva[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2qxS|I1QTl{OUW4
MKN-45 MnTOSpVv[3Srb36gRZN{[Xl? NYrZbJB6OTBxNUCvNVAxKM7:TR?= M17uUlQ5KGh? NHXWfFRFVVOR MnjE[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MknQNlQ6QTJ7NUi=
C666-1 NHLkWWZEgXSxdH;4bYNqfHliQYPzZZk> NWLwXWYyOjBvOECg{txO NEDkZlQzPCCq MnTn[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> MWiyOFg2PDh|OB?=
CNE-1 NEja[2VEgXSxdH;4bYNqfHliQYPzZZk> MoHsNlAuQDBizszN MoOyNlQhcA>? NHzaU4dl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MXGyOFg2PDh|OB?=
CNE-2 M3;K[WN6fG:2b4jpZ4l1gSCDc4PhfS=> M4LQT|IxNThyIN88US=> MXmyOEBp MV7k[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MorJNlQ5PTR6M{i=
C666-1 MlHCR5l1d3SxeHnjbZR6KEG|c3H5 MYq2NEDPxE1? NFvhfXA4KGR? MVjlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= MnK3NlQ5PTR6M{i=
CNE-1 MojxR5l1d3SxeHnjbZR6KEG|c3H5 MkPROlAh|ryP M2WzdFch\A>? M4fZeIVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NWTveZJROjR6NUS4N|g>
SNU-1041 NFvvelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmwMVQxKM7:TR?= MnnWOFghcA>? M1XLNIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MYqyOFY6OjdyMx?=
SNU-1041 MUTGeY5kfGmxbjDBd5NigQ>? MoS5NlAwOzBizszN MWG0JIg> M2jOO4lv\HWlZYOg[ZhxemW|c3nvckBw\sLiQ1jPVEwhT1KSN{lCpIFv\MLiWFLQNeKh[XRidHjlJHJPSSCuZY\lcOKh NH:3VlQzPDZ7MkewNy=>
SNU-1041 MYXGeY5kfGmxbjDBd5NigQ>? NVTlcolNOC12MDFOwG0> MlG5OEBp Mom5eZAuemWpdXzheIV{KEOKT2FCpIFnfGW{IITy[YF1dWWwdDD3bZRpKGirZ3igZ49v[2WwdILheIlwdnN? MoWxNlQ3QTJ5MEO=
SGC-7901 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXzXmY2OC1zMkWg{txO M1XHVFI1NzR6L{eyJIg> Mn\2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHi2PZIzPDZ5NkO5OC=>
SGC-7901 MVzBdI9xfG:|aYOgRZN{[Xl? MYGxNFAh|ryP NV\uVm1pPzJiaB?= MYLpcoR2[2W|IHHwc5B1d3Orcx?= MUSyOFY4PjN7NB?=
SGC-7901 NFPkW4FHfW6ldHnvckBCe3OjeR?= NVPLdW5YPzVxMUCwM|EzPSEQvF2= MYmyOE81QC95MjDo MXjpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?= NHHEO4ozPDZ5NkO5OC=>
LMeC  NV7Hd21jTnWwY4Tpc44hSXO|YYm= NVXC[WdQOjBxNUCg{txO M4n4dVQ5KGh? MXnk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJicILveIVqdg>? MmjRNlQ3PTZ5NE[=
CMeC-1 NFLEPGNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MknnNlAwPTBizszN M4j1SFQ5KGh? MV\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NITU[3czPDZ3Nke0Oi=>
LMeC NWfSfItQS2WubDDWbYFjcWyrdImgRZN{[Xl? MmHzNlAwPTBizszN MXu0PEBp NUnUT5FmcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NFSxc4szPDZ3Nke0Oi=>
CMeC-1 MUXGeY5kfGmxbjDBd5NigQ>? Mo\RNlAwPTBizszN MVu0PEBp NUjvZmticW6mdXPld{BIOS2VIHHydoV{fA>? MXiyOFY2Pjd2Nh?=
LMeC NXy5OpQzTnWwY4Tpc44hSXO|YYm= NHTSenYzOC93MDFOwG0> NYrBeolwPDhiaB?= NXnQdHU2cW6mdXPld{BIOS2VIHHydoV{fA>? MYSyOFY2Pjd2Nh?=
CMeC-1 NH\jfHVHfW6ldHnvckBCe3OjeR?= NEizXIIzOC93MDFOwG0> NFPOSG01QCCq NV\5WFR1\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Ml71NlQ3PTZ5NE[=
LMeC NVTseFJuTnWwY4Tpc44hSXO|YYm= MnXCNlAwPTBizszN NHzXeIM1QCCq NXXVcHlm\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2f1elI1PjV4N{S2
CMeC-1 MknRSpVv[3Srb36gRZN{[Xl? NIq4T4kzOC93MDFOwG0> NX;KRmE1PDhiaB?= MVrpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u NGiwZXgzPDZ3Nke0Oi=>
LMeC NXqxNoNkTnWwY4Tpc44hSXO|YYm= NFm4XG4zOC93MDFOwG0> Mlj5OFghcA>? NXy4cHlScW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? NEXZb2czPDZ3Nke0Oi=>
OVCAR-3 M3PSZmNmdGxiVnnhZoltcXS7IFHzd4F6 NWT0eIRyOTBiwsXN M3riXFEhcA>? NInEPGpmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh MWKyOFUzODJ{Nx?=
OVCAR-3 NEnXcFRCeG:ydH;zbZMhSXO|YYm= M2ftcFExKML3TR?= NIDVO3MyKGh? NH3VRnhxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB? Mk\HNlQ2OjB{Mke=
OVCAR-3 MV3GeY5kfGmxbjDBd5NigQ>? NXT1WVR7OTBiwsXN MmP4NUBp MWjlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?= NXXlVppYOjR3MkCyNlc>
OVCAR-3 NEOzSGVHfW6ldHnvckBCe3OjeR?= M2LIdlExKML3TR?= MnryNUBp NF;oPGNld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw> MljPNlQ2OjB{Mke=
OVCAR-3 NGnYOllHfW6ldHnvckBCe3OjeR?= MYCxNEDDvU1? Ml\kNUBp MWLpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> NET4dJUzPDV{MEKyOy=>
CF33 NG\rNHJHfW6ldHnvckBCe3OjeR?= M3P6b|ExOCEQvF2= NX7rS|BxOjRiaB?= MWLpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIFPPXE0zKHC{b4TlbY4h\XiycnXzd4lwdg>? M{\xPVI1PTB|N{iy
CF33 NIm2WFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC2NVAuOTByIN88US=> M4jjblAuPCCm NH;YNldqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmHWNlQ2ODN5OEK=
CF33 MUfGeY5kfGmxbjDBd5NigQ>? MWGxNE0yODBizszN NGS5b201NTJ2IHi= MV\k[YNz\WG|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q> MV:yOFUxOzd6Mh?=
LNCaP M2DkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP1bJQzNzVxMUCg{txO MX25OkBp M2DnR4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= MWqyOFI6Pjl5OB?=
LNCaP MUHBdI9xfG:|aYOgRZN{[Xl? MkK3Nk82NzFyIN88US=> NF7wSJY6PiCq NV\ubHh4cW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> MmTKNlQzQTZ7N{i=
PC-3  NWXqWWhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMVUxKM7:TR?= NV[2dIl6PDkkgJno M3m1eYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NEDrbZkzPDF{N{i4Ni=>
PC-3  MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHG1XowxNTFyMDFOwG0> NFHlbXc4OiCq MYrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHX4SoszPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
臨床試験 Celecoxib is currently in Phase II clinical trials in patients with recurrent respiratory papillomatosis.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

細胞アッセイ: [2]

細胞株 HNE1 and CNE1-LMP1
濃度 0-75 μM
反応時間 48 hours
実験の流れ The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

動物実験: [1]

動物モデル A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
製剤 Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Celecoxib SDF
分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管 2年-20℃
6月-80℃in solvent
別名 SC 58635
溶解度 (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
エタノール 33 mg/mL (86.53 mM)
<1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

文献中の引用 (6)

Frequently Asked Questions

  • Question 1
    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

    Answer: For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related COX 阻害剤

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • Indomethacin

    Indomethacin(Indocid, Indocin) is a non-steroidal anti-inflammatory compound commonly used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively.

  • Aspirin

    Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolacは非選択COX阻害剤、人間COX-1とCOX-2に作用する時、IC50がそれぞれ1.23 µM と3.50 µM になる。

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

最近チェックしたアイテム

Tags: Celecoxibを買う | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ